Prevention of diabetes macrovascular complications and heart failure

Sattar, N. (2021) Prevention of diabetes macrovascular complications and heart failure. Endocrinology and Metabolism Clinics of North America, 50(3), pp. 415-430. (doi: 10.1016/j.ecl.2021.05.004) (PMID:34399954)

[img] Text
250624.pdf - Accepted Version
Restricted to Repository staff only until 12 July 2022.



Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3 decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be achieved from large-scale weight loss, which ongoing trials are testing, and from delaying diabetes in those at highest risk. Finally, recent outcome trials support a role for (1) sodium/glucose cotransporter-2 inhibitors, which lower major adverse cardiovascular events but incident heart failure more strongly, and (2) glucagon-like peptide-1 receptor agonists, which lower atherothrombotic outcomes more consistently, including stroke and peripheral arterial disease.

Item Type:Articles
Keywords:LDL-cholesterol, obesity, SGLT2i, countries, hypertension, ethnicity, GLP-1RA, metformin.
Glasgow Author(s) Enlighten ID:Sattar, Professor Naveed
Authors: Sattar, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Endocrinology and Metabolism Clinics of North America
ISSN (Online):1558-4410
Published Online:12 July 2021

University Staff: Request a correction | Enlighten Editors: Update this record